Vancomycin-resistant enterococci (VRE) screening and isolation in the general medicine ward: a cost-effectiveness analysis

Table 2 Base-case results (health and economic outcomes)

Outcomes	VRE screening and isolation	No VRE screening and isolation	Difference^a (%)
Non-isolated cases	11/1000	60/1000	−49/1000 (82%)
Healthcare-associated VRE-colonisation	2/1000	8/1000	−6/1000 (73%)
Infected cases	5.7/1000	6.3/1000	−0.6/1000 (10%)
VRE-related bacteremia	2.6/1000	2.8/1000	−0.2/1000 (7%)
Other VRE infections (e.g. UTI)	3.2/1000	3.6/1000	−0.4/1000 (12%)
Deaths subsequent to VRE infection	0.5/1000	0.6/1000	−0.1/1000 (8%)
ICER ($/QALY)			7850
Total costs ($)	118.37	6.72	112
Total QALY gained	20.5607	20.5465	0.0142

^aDifference for health outcomes were calculated by subtracting “no VRE screening and isolation strategy” outcomes from “VRE screening and isolation strategy” outcomes. Percentage change was calculated relative to “no VRE screening and isolation strategy” outcomes
ICER incremental cost-effectiveness ration, QALY quality-adjusted life years, UTI urinary tract infection, VRE vancomycin-resistant enterococci

ISSN: 2047-2994